Venturi Wealth Management LLC Boosts Holdings in Hologic, Inc. (NASDAQ:HOLX)

Venturi Wealth Management LLC boosted its stake in Hologic, Inc. (NASDAQ:HOLX) by 156.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 428 shares of the medical equipment provider’s stock after acquiring an additional 261 shares during the period. Venturi Wealth Management LLC’s holdings in Hologic were worth $31,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HOLX. CIBC Asset Management Inc grew its holdings in Hologic by 4.6% during the fourth quarter. CIBC Asset Management Inc now owns 35,529 shares of the medical equipment provider’s stock valued at $2,561,000 after purchasing an additional 1,556 shares during the period. AlphaCentric Advisors LLC purchased a new position in shares of Hologic during the 4th quarter valued at $549,000. Principal Financial Group Inc. grew its stake in shares of Hologic by 0.6% during the 4th quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider’s stock worth $19,547,000 after acquiring an additional 1,606 shares during the period. Asset Management One Co. Ltd. increased its holdings in Hologic by 58.9% in the 4th quarter. Asset Management One Co. Ltd. now owns 145,028 shares of the medical equipment provider’s stock worth $10,529,000 after acquiring an additional 53,762 shares during the last quarter. Finally, Empowered Funds LLC increased its holdings in Hologic by 280.3% in the 4th quarter. Empowered Funds LLC now owns 13,704 shares of the medical equipment provider’s stock worth $988,000 after acquiring an additional 10,101 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. William Blair reiterated an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. UBS Group raised their price objective on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Royal Bank of Canada lowered their target price on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a report on Thursday, February 6th. Leerink Partners downgraded Hologic from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Finally, Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective on the stock. in a research note on Monday, February 3rd. Ten investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Hologic currently has an average rating of “Moderate Buy” and an average target price of $85.77.

Hologic Trading Up 0.3 %

Shares of HOLX opened at $65.23 on Wednesday. Hologic, Inc. has a 1-year low of $62.69 and a 1-year high of $84.67. The company has a market capitalization of $14.64 billion, a P/E ratio of 20.58, a P/E/G ratio of 2.14 and a beta of 0.98. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm’s 50 day simple moving average is $69.62 and its 200 day simple moving average is $76.28.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.88% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.